Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921435 | 0.96 | KCNA3 (0.43) | CYP1A2CYP2C19CYP2D6MAPK1KCNA3 | |
| SCHEMBL1712248 | 0.95 | KCNA3 (0.42) | CYP1A2CYP2C19CYP2D6MAPK1KCNA3 | |
| SCHEMBL919376 | 0.95 | KCNA3 (0.42) | CYP1A2CYP2C19CYP2D6MAPK1KCNA3 | |
| SCHEMBL920697 | 0.95 | KCNA3 (0.42) | CYP1A2CYP2C19CYP2D6MAPK1KCNA3 | |
| SCHEMBL517096 | 0.91 | PKM (0.38) | CYP1A2CYP2C19CYP2D6MAPK1KCNA3 | |
| SCHEMBL6637667 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2D6MAPK1MEN1 | |
| SCHEMBL3163767 | 0.86 | KDM4E (0.41) | CYP1A2CYP2C19CYP2D6MAPK1KDM4E | |
| SCHEMBL3169298 | 0.86 | KDM4E (0.41) | CYP1A2CYP2C19CYP2D6MAPK1KDM4E | |
| SCHEMBL5704638 | 0.84 | KCNA3 (0.42) | MAPK1KCNA3LTA4HHTR1BKDM4E | |
| SCHEMBL131741 | 0.83 | LTA4H (0.53) | CYP1A2CYP2C19CYP2D6MAPK1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829572-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS | Vyne Therapeutics Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020023898-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS | MENLO THERAPEUTICS INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-2247575-B1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-23 | — | — | EP | disclosed |
| US-8580813-B2 | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| CN-101981006-B | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2013-08-28 | — | — | CN | disclosed |
| EP-2240482-B1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| CN-101970437-B | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2013-04-03 | — | — | CN | disclosed |
| US-8211885-B2 | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2345328-A1 | COMPOSITION FOR AGRICULTURAL USE | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-2247575-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | disclosed |
| EP-2248423-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| EP-2240482-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009095163-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095162-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0190444-B1 | OPTICAL-RECORDING MEDIUM | BASF Aktiengesellschaft (DE) | 1988-09-21 | — | — | EP | disclosed |
| EP-0190444-A1 | Optical-recording medium | BASF Aktiengesellschaft (DE) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | H1-0, H1-3, H1-2 | CYP1A2 2061/4885CYP2C19 2943/4885CYP2D6 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.